Johnson & Johnson
JNJ152.280USD
+0.090+0.06%
終値 06/25, 16:00（ET）15分遅れの株価
366.33B時価総額
26.04直近12ヶ月PER
詳細情報 Johnson & Johnson 企業名
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. The Company operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolism. Medicines in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, cardiovascular, and vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eyecare professionals, and clinics.
企業情報
企業コードJNJ
会社名Johnson & Johnson
上場日Sep 25, 1944
設立日1887
最高経営責任者「CEO」Mr. Joaquin Boix Duato
従業員数138100
証券種類Ordinary Share
決算期末Sep 25
本社所在地One Johnson & Johnson Plaza
都市NEW BRUNSWICK
証券取引所NYSE Consolidated
国United States of America
郵便番号08933
電話番号17325242455
ウェブサイトhttps://www.jnj.com/
企業コードJNJ
上場日Sep 25, 1944
設立日1887
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Joaquin Boix Duato
Mr. Joaquin Boix Duato
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
276.91K
-32.09%
Ms. Jennifer L. Taubert
Ms. Jennifer L. Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
Executive Vice President, Worldwide Chairman, Innovative Medicine
178.01K
+14.96%
Ms. Kathryn E. Wengel
Ms. Kathryn E. Wengel
Executive Vice President, Chief Technology Officer and Risk Officer
Executive Vice President, Chief Technology Officer and Risk Officer
94.62K
+14.54%
Mr. Joseph J. Wolk
Mr. Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
84.95K
+4.05K%
Prof. Dr. John C. Reed, M.D., Ph.D.
Prof. Dr. John C. Reed, M.D., Ph.D.
Executive Vice President - Innovative Medicine, Research and Development
Executive Vice President - Innovative Medicine, Research and Development
29.80K
+91.71%
Ms. Vanessa Broadhurst
Ms. Vanessa Broadhurst
Executive Vice President - Global Corporate Affairs
Executive Vice President - Global Corporate Affairs
23.59K
+18.96%
Ms. Kristen Mulholland
Ms. Kristen Mulholland
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
14.12K
+20.79%
Ms. Elizabeth (Liz) Forminard
Ms. Elizabeth (Liz) Forminard
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
10.90K
+30.72%
Mrs. Anne M. Mulcahy
Mrs. Anne M. Mulcahy
Independent Director
Independent Director
8.41K
+3.87%
Mr. Hubert Joly
Mr. Hubert Joly
Independent Director
Independent Director
5.00K
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Joaquin Boix Duato
Mr. Joaquin Boix Duato
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
276.91K
-32.09%
Ms. Jennifer L. Taubert
Ms. Jennifer L. Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
Executive Vice President, Worldwide Chairman, Innovative Medicine
178.01K
+14.96%
Ms. Kathryn E. Wengel
Ms. Kathryn E. Wengel
Executive Vice President, Chief Technology Officer and Risk Officer
Executive Vice President, Chief Technology Officer and Risk Officer
94.62K
+14.54%
Mr. Joseph J. Wolk
Mr. Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
84.95K
+4.05K%
Prof. Dr. John C. Reed, M.D., Ph.D.
Prof. Dr. John C. Reed, M.D., Ph.D.
Executive Vice President - Innovative Medicine, Research and Development
Executive Vice President - Innovative Medicine, Research and Development
29.80K
+91.71%
Ms. Vanessa Broadhurst
Ms. Vanessa Broadhurst
Executive Vice President - Global Corporate Affairs
Executive Vice President - Global Corporate Affairs
23.59K
+18.96%
収益内訳
通貨: USD更新時刻: Sun, Apr 6
通貨: USD更新時刻: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
事業別USD
会社名
収益
比率
Oncology-DARZALEX
11.67B
13.14%
Immunology-STELARA
10.36B
11.67%
Interventional Solutions
7.71B
8.68%
Surgery-General
5.36B
6.03%
Surgery-Advanced
4.49B
5.05%
Other
49.24B
55.43%
地域別USD
会社名
収益
比率
United States
50.30B
56.63%
International
38.52B
43.37%
Europe
20.21B
22.76%
Asia-Pacific, Africa
13.59B
15.30%
Western Hemisphere, excluding U.S.
4.71B
5.31%
事業別
地域別
事業別USD
会社名
収益
比率
Oncology-DARZALEX
11.67B
13.14%
Immunology-STELARA
10.36B
11.67%
Interventional Solutions
7.71B
8.68%
Surgery-General
5.36B
6.03%
Surgery-Advanced
4.49B
5.05%
Other
49.24B
55.43%
株主
更新時刻: Tue, May 13
更新時刻: Tue, May 13
株主統計
種類
株主統計
株主統計
比率
The Vanguard Group, Inc.
9.68%
State Street Global Advisors (US)
5.56%
BlackRock Institutional Trust Company, N.A.
5.37%
Geode Capital Management, L.L.C.
2.47%
JP Morgan Asset Management
1.47%
Other
75.46%
株主統計
株主統計
比率
The Vanguard Group, Inc.
9.68%
State Street Global Advisors (US)
5.56%
BlackRock Institutional Trust Company, N.A.
5.37%
Geode Capital Management, L.L.C.
2.47%
JP Morgan Asset Management
1.47%
Other
75.46%
種類
株主統計
比率
Investment Advisor/Hedge Fund
33.47%
Investment Advisor
29.37%
Research Firm
3.09%
Bank and Trust
2.18%
Pension Fund
2.17%
Insurance Company
1.64%
Sovereign Wealth Fund
1.39%
Hedge Fund
0.57%
Foundation
0.10%
Other
26.00%
機関投資家保有株
更新時刻: Thu, Feb 20
更新時刻: Thu, Feb 20
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q1
5936
1.78B
74.10%
-2.10K
2024Q4
5953
1.78B
74.14%
+8.28M
2024Q3
5699
1.77B
73.47%
+2.69M
2024Q2
5691
1.75B
72.75%
+9.12M
2024Q1
5685
1.73B
71.58%
-6.08M
2023Q4
5686
1.72B
71.40%
-7.80M
2023Q3
5524
1.72B
71.21%
-159.24M
2023Q2
5528
1.87B
71.81%
+6.27M
2023Q1
5490
1.85B
71.21%
-28.44M
2022Q4
5447
1.87B
71.55%
+6.54M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
The Vanguard Group, Inc.
231.82M
9.62%
+1.80M
+0.78%
Dec 31, 2024
State Street Global Advisors (US)
134.46M
5.58%
+210.35K
+0.16%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
130.00M
5.39%
+2.12M
+1.65%
Dec 31, 2024
Geode Capital Management, L.L.C.
57.67M
2.39%
+1.56M
+2.78%
Dec 31, 2024
JP Morgan Asset Management
24.04M
1%
+5.40M
+29.00%
Dec 31, 2024
State Farm Insurance Companies
31.68M
1.31%
--
--
Dec 31, 2024
Norges Bank Investment Management (NBIM)
30.36M
1.26%
+1.26M
+4.34%
Dec 31, 2024
Morgan Stanley Smith Barney LLC
22.91M
0.95%
-654.88K
-2.78%
Dec 31, 2024
Wellington Management Company, LLP
24.36M
1.01%
+431.20K
+1.80%
Dec 31, 2024
BlackRock Asset Management Ireland Limited
19.88M
0.82%
+587.38K
+3.05%
Dec 31, 2024
詳細を見る
関連ETF
更新時刻: Fri, Jun 6
更新時刻: Fri, Jun 6
銘柄名
比率
iShares U.S. Pharmaceuticals ETF
22.25%
FT Vest DJIA Dogs 10 Target Income ETF
10.48%
Touchstone Strategic Income ETF
7.96%
Franklin Income Focus ETF
7.87%
JPMorgan Healthcare Leaders ETF
7.74%
First Trust NASDAQ Pharmaceuticals ETF
7.51%
Health Care Select Sector SPDR Fund
7.31%
Proshares Ultra Health Care
7.06%
iShares U.S. Healthcare ETF
7%
American Century Focused Large Cap Value ETF
6.4%
詳細を見る
iShares U.S. Pharmaceuticals ETF
比率22.25%
FT Vest DJIA Dogs 10 Target Income ETF
比率10.48%
Touchstone Strategic Income ETF
比率7.96%
Franklin Income Focus ETF
比率7.87%
JPMorgan Healthcare Leaders ETF
比率7.74%
First Trust NASDAQ Pharmaceuticals ETF
比率7.51%
Health Care Select Sector SPDR Fund
比率7.31%
Proshares Ultra Health Care
比率7.06%
iShares U.S. Healthcare ETF
比率7%
American Century Focused Large Cap Value ETF
比率6.4%
配当金
過去5年間の配当金総支払額は
56.79B
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
Jan 02, 2025
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Mar 04, 2025 going ex on Feb 18, 2025
Feb 18, 2025
Mar 04, 2025
Feb 18, 2025
Oct 15, 2024
JNJ.NB Final Cash Dividend of gross USD 1.24 paid on Dec 10, 2024 going ex on Nov 26, 2024
Nov 26, 2024
Dec 10, 2024
Nov 26, 2024
Jul 17, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Sep 10, 2024 going ex on Aug 27, 2024
Aug 27, 2024
Sep 10, 2024
Aug 27, 2024
Apr 16, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Jun 04, 2024 going ex on May 20, 2024
May 21, 2024
Jun 04, 2024
May 20, 2024
Jan 02, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Mar 05, 2024 going ex on Feb 16, 2024
Feb 20, 2024
Mar 05, 2024
Feb 16, 2024
Oct 19, 2023
JNJ.NB Final Cash Dividend of gross USD 1.19 paid on Dec 05, 2023 going ex on Nov 20, 2023
Nov 21, 2023
Dec 05, 2023
Nov 20, 2023
Jul 20, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Sep 07, 2023 going ex on Aug 25, 2023
Aug 28, 2023
Sep 07, 2023
Aug 25, 2023
Apr 18, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Jun 06, 2023 going ex on May 22, 2023
May 23, 2023
Jun 06, 2023
May 22, 2023
Jan 03, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.13 paid on Mar 07, 2023 going ex on Feb 17, 2023
Feb 21, 2023
Mar 07, 2023
Feb 17, 2023
Oct 18, 2022
JNJ.NB Final Cash Dividend of gross USD 1.13 paid on Dec 06, 2022 going ex on Nov 21, 2022
Nov 22, 2022
Dec 06, 2022
Nov 21, 2022
詳細を見る
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
